diabetestalk.net

To Donald Trump, From An American With Diabetes

To Donald Trump, From an American With Diabetes

To Donald Trump, From an American With Diabetes

Dear President Trump,
Today you were sworn into become President of the United States.
As you were being sworn in, thousands of insulin dependent diabetics had to make a choice. Should they take a full dose of insulin and ensure their blood sugars don’t go high, or should they save some in an effort to try and make it through the month? I am one of the lucky ones, I have the resources to have private insurance. However, even with private insurance my Novolog insulin runs me over $400 out of pocket. Now imagine if I didn’t have insurance, that number would be in the thousands.
Sir, there are millions of Americans who depend on the Affordable Care Act to survive. For these Americans, the ACA isn’t merely some bill or something to argue over in the Senate, it’s a matter of life and death.
Please Donald, before you repeal the ACA, be sure to have a replacement. Why don’t you incorporate the millions of Americans who live with a chronic illness into the discussion of a replacement? The ACA isn’t perfect, but it has saved lives.
Drug prices are still too high, and far too many Americans go without vital medication because they cannot afford it, but the ACA has granted millions access to affordable health insurance, something that seemed like a dream 10 years ago.
Donald, I would invite you to listen to those with chronic illnesses and other health problems. Listen to the American people.
After all, didn’t the American people put you in office in the first place?
Lead photo by Thinkstock Images Continue reading

Rate this article
Total 1 ratings
Popular Diabetes Medication Linked to Kidney Failure  Americas Lawyer

Popular Diabetes Medication Linked to Kidney Failure Americas Lawyer


Popular Diabetes Medication Linked to Kidney Failure Americas Lawyer
According to latest data from the Centers for Disease Control, more than 29-million Americans suffer from diabetes, and nearly one of four people with the disease arent even aware that they have it. Even worse, as many as 86-million Americans currently suffer from pre-diabetes, and if preemptive measures arent taken they too will be diagnosed with full blown diabetes in a matter of years. With so many people suffering from both type one and type two diabetes, Big Pharma saw an opportunity to make a huge profit. In the rush to cash in on the diabetic epidemic they cut corners. They created a product thats causing as much harm, if not more, than the actual disease itself. That product is called Invokana.
Papantonio: According to latest data from the Centers for Disease Control, more than 29-million Americans suffer from diabetes, and nearly one of four people with the disease arent even aware that they have it. Even worse, as many as 86-million Americans currently suffer from pre-diabetes, and if preemptive measures arent taken they too will be diagnosed with full blown diabetes in a matter of years. With so many people suffering from both type one and type two diabetes, Big Pharma saw an opportunity to make a huge profit. In the rush to cash in on the diabetic epidemic they cut corners. They created a product thats causing as much harm, if not more, than the actual disease itself. That product is called Invokana.
Invokana was developed by Janssen, an offshoot of Johnson & Johnson. Unlike other diabete Continue reading

Remote type 2 education platform selected for NHS Innovation

Remote type 2 education platform selected for NHS Innovation

A low-cost, online self-management platform for people with diabetes and a fully remote programme of type 2 diabetes structured education are among the latest technologies selected to join the NHS Innovation Accelerator (NIA).
A total of 11 innovations have been selected as part of an event to launch the third year of this NHS England initiative, delivered in partnership with England’s 15 Academic Health Science Networks (AHSNs).
The NIA has supported the uptake and spread of 25 high-impact, evidence-based innovations across 799 NHS organisations since it launched in July 2015.
Each of the new innovations joining the NIA this year offer solutions to key challenges in primary care, urgent and emergency care and mental health. Recruitment onto the NIA follows an international call and robust selection process, including review by a collegiate of over 100 assessors and the National Institute for Health and Care Excellence (NICE).
Simon Stevens, NHS England chief executive said: “Modern medicine is on the cusp of a huge shift in how care is delivered, and practical innovations like these show how NHS patients will now directly benefit. More tests and patient monitoring will be done at home or on the move, without the need to pitch up to a doctor’s appointment or hospital outpatients.”
My Diabetes My Way is an interactive website for people with condition, providing comprehensive information about medication, self-management and lifestyle. online self-management platform for people with diabetes. Recent figures suggested that 88 per cent of users, felt it had helped them Continue reading

Animal Models of Type 2 Diabetes: The GK Rat

Animal Models of Type 2 Diabetes: The GK Rat


Animal Models of Type 2 Diabetes: The GK Rat
Animal Models of Type 2 Diabetes: The GK Rat
Studying the long-term complications of diabetic pathology is more relevant than ever, driving increased interest in animal models of type 2 diabetes. According to the World Health Organization (WHO) the number of people with diabetes (includes both type 1 and type 2) has risen from 108 million in 1980 to 422 million in 2014.
"[Diabetes] is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves. Adults with diabetes have a 2-3-fold increased risk of heart attacks and strokes. Combined with reduced blood flow, neuropathy in the feet increases the chance of foot ulcers, infection and eventual need for limb amputation. Diabetic retinopathy is an important cause of blindness and occurs as a result of long-term accumulated damage to the small blood vessels in the retina. 2.6% of global blindness can be attributed to diabetes. Diabetes is among the leading causes of kidney failure." (WHO Media Center, 2016).
There are a variety of mouse and rat models which can be used to study aspects of type 2 diabetes:
Varying aspects and severity of complications
+ More robust diet induced obesity in C57BL/6NTac (Gareski T, 2009)
Studying Long-term Pathology in Animal Models of Type 2 Diabetes
The ob/ob and db/db mice, as well as the Zucker Diabetic Fatty rat, are all well-characterized and frequently-used diabetic models which exhibit a mutation in the leptin (ob/ob) or lep Continue reading

Resistance Training for Diabetes Prevention and Therapy: Experimental Findings and Molecular Mechanisms

Resistance Training for Diabetes Prevention and Therapy: Experimental Findings and Molecular Mechanisms


Resistance Training for Diabetes Prevention and Therapy: Experimental Findings and Molecular Mechanisms
1Institute for Nutritional Sciences and Physiology, University for Health Sciences, Medical Informatics and Technology, A-6060 Hall in Tirol, Eduard Wallnoefer-Zentrum 1, Austria
2Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
1Institute for Nutritional Sciences and Physiology, University for Health Sciences, Medical Informatics and Technology, A-6060 Hall in Tirol, Eduard Wallnoefer-Zentrum 1, Austria
2Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
Received 2013 Oct 31; Accepted 2013 Dec 9.
Copyright 2013 B. Strasser and D. Pesta.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article has been cited by other articles in PMC.
Type 2 diabetes mellitus (T2D) is characterized by insulin resistance, impaired glycogen synthesis, lipid accumulation, and impaired mitochondrial function. Exercise training has received increasing recognition as a cornerstone in the prevention and treatment of T2D. Emerging research suggests that resistance training (RT) has the power to combat metabolic dysfunction in patients with T2D and seems to be an effective measure to improve overall metabolic health and reduce metabolic risk factors in diabetic patients. However, there is limited Continue reading

No more pages to load

Popular Articles

Related Articles